The ATR Inhibitor Ceralasertib Potentiates Cancer Checkpoint Immunotherapy by Regulating the Tumor Microenvironment
Elizabeth L. Hardaker,Emilio Sanseviero,Ankur Karmokar,Devon Taylor,Marta Milo, Chrysis Michaloglou,Adina Hughes, Mimi Mai,Matthew King,Anisha Solanki,Lukasz Magiera,Ricardo Miragaia,Gozde Kar,Nathan Standifer,Michael Surace, Shaan Gill,Alison Peter,Sara Talbot,Sehmus Tohumeken, Henderson Fryer,Ali Mostafa,Kathy Mulgrew,Carolyn Lam,Scott Hoffmann,Daniel Sutton,Larissa Carnevalli,Fernando J. Calero-Nieto,Gemma N. Jones,Andrew J. Pierce,Zena Wilson, David Campbell, Lynet Nyoni,Carla P. Martins, Tamara Baker, Gilberto Serrano de Almeida,Zainab Ramlaoui, Abdel Bidar, Benjamin Phillips,Joseph Boland,Sonia Iyer,J. Carl Barrett,Arsene-Bienvenu Loembé,Serge Y. Fuchs,Umamaheswar Duvvuri,Pei-Jen Lou,Melonie A. Nance, Carlos Alberto Gomez Roca,Elaine Cadogan, Susan E. Critichlow, Steven Fawell,Mark Cobbold,Emma Dean,Viia Valge-Archer,Alan Lau,Dmitry I. Gabrilovich, Simon T. Barry NATURE COMMUNICATIONS（2024）
Key words
Tumor Microenvironment,Cancer Immunoediting,ATM and ATR Kinases
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper